Menley & James entering cough/cold sector with OTC version of Adams Labs' Humibid.
This article was originally published in The Tan Sheet
Executive Summary
MENLEY & JAMES TO ENTER COUGH/COLD SECTOR WITH OTC VERSION OF HUMIBID, a prescription multisymptom product manufactured and sold by Medeva PLC subsidiary Adams Labs. Menley & James announced March 20 that it will begin shipping the OTC product to trade in June; the product will be available regionally in drug stores and mass merchandisers beginning in early fall. The company is targeting nationwide availability by the start of the 1997 cold season.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning